According to a research report published by Goldman Sachs, BeiGene's second-quarter product sales revenue was US$1.68 billion, up 29% year on year, slightly higher than the bank and market expectations. The global sales performance of the core product Baiyuze continued to be strong, with a year-on-year increase of 31% to US$1.25 billion, further consolidating its leading position in the global BTK inhibitor market, with a market share of 38%. Its sales in the US market increased 31% year-on-year to US$893 million, higher than the bank's expectations of US$822 million. Management raised its 2026 full-year guidance again in response to strong performance in the second quarter. Total revenue guidance was raised from US$6.3 billion to US$6.5 billion to US$6.8 billion; non-GAAP operating profit was raised from US$1.45 billion to US$1.55 billion to US$1.7 billion to US$1.8 billion. Goldman Sachs, on the other hand, raised its earnings forecast per share from 2026 to 2028 and raised its target price for US stocks from $414.46 to $441.3, maintaining a “buy” rating.

According to a research report published by Goldman Sachs, BeiGene's second-quarter product sales revenue was US$1.68 billion, up 29% year on year, slightly higher than the bank and market expectations. The global sales performance of the core product Baiyuze continued to be strong, with a year-on-year increase of 31% to US$1.25 billion, further consolidating its leading position in the global BTK inhibitor market, with a market share of 38%. Its sales in the US market increased 31% year-on-year to US$893 million, higher than the bank's expectations of US$822 million. Management raised its 2026 full-year guidance again in response to strong performance in the second quarter. Total revenue guidance was raised from US$6.3 billion to US$6.5 billion to US$6.8 billion; non-GAAP operating profit was raised from US$1.45 billion to US$1.55 billion to US$1.7 billion to US$1.8 billion. Goldman Sachs, on the other hand, raised its earnings forecast per share from 2026 to 2028 and raised its target price for US stocks from $414.46 to $441.3, maintaining a “buy” rating.